## Yu Fujita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6662323/publications.pdf Version: 2024-02-01



ΥΠ ΕΠΠΤΑ

#	Article	IF	CITATIONS
1	The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell, 2016, 167, 1525-1539.e17.	28.9	318
2	Versatile roles of extracellular vesicles in cancer. Journal of Clinical Investigation, 2016, 126, 1163-1172.	8.2	261
3	The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer. Molecular Therapy, 2015, 23, 717-727.	8.2	218
4	Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesis. Journal of Extracellular Vesicles, 2015, 4, 28388.	12.2	187
5	Metformin attenuates lung fibrosis development via NOX4 suppression. Respiratory Research, 2016, 17, 107.	3.6	178
6	Extracellular vesicle transfer of cancer pathogenic components. Cancer Science, 2016, 107, 385-390.	3.9	175
7	Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer, 2015, 88, 154-159.	2.0	153
8	Extracellular vesicles in lung microenvironment and pathogenesis. Trends in Molecular Medicine, 2015, 21, 533-542.	6.7	149
9	Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases. Journal of Clinical Medicine, 2018, 7, 355.	2.4	128
10	Emerging role of extracellular vesicles as a senescence-associated secretory phenotype: Insights into the pathophysiology of lung diseases. Molecular Aspects of Medicine, 2018, 60, 92-103.	6.4	126
11	PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis. Autophagy, 2019, 15, 510-526.	9.1	116
12	Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5â^'/â^' mice. Nature Communications, 2019, 10, 1492.	12.8	114
13	Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth. Cell Reports, 2020, 30, 1753-1766.e6.	6.4	105
14	Targeting the Warburg effect via <scp>LDHA</scp> inhibition engages <scp>ATF</scp> 4 signaling for cancer cell survival. EMBO Journal, 2018, 37, .	7.8	103
15	Involvement of PARK2-Mediated Mitophagy in Idiopathic Pulmonary Fibrosis Pathogenesis. Journal of Immunology, 2016, 197, 504-516.	0.8	102
16	RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals, 2013, 6, 223-250.	3.8	78
17	Intercellular Communication by Extracellular Vesicles and Their MicroRNAs in Asthma. Clinical Therapeutics, 2014, 36, 873-881.	2.5	75
18	Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4. Autophagy, 2017, 13, 1420-1434.	9.1	74

Υυ Γυjita

#	Article	IF	CITATIONS
19	Human bronchial epithelial cellâ€derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGFâ€î²â€WNT crosstalk. Journal of Extracellular Vesicles, 2021, 10, e12124.	12.2	74
20	Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respiratory Research, 2017, 18, 114.	3.6	72
21	Extracellular Vesicles from Fibroblasts Induce Epithelial-Cell Senescence in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 623-636.	2.9	63
22	Extracellular Vesicles in Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences, 2016, 17, 1801.	4.1	62
23	Development of Small RNA Delivery Systems for Lung Cancer Therapy. International Journal of Molecular Sciences, 2015, 16, 5254-5270.	4.1	57
24	The Impact of Extracellular Vesicle-Encapsulated Circulating MicroRNAs in Lung Cancer Research. BioMed Research International, 2014, 2014, 1-8.	1.9	54
25	Extracellular vesicles in lung cancer—From bench to bedside. Seminars in Cell and Developmental Biology, 2017, 67, 39-47.	5.0	47
26	A novel platform to enable inhaled naked RNAi medicine for lung cancer. Scientific Reports, 2013, 3, 3325.	3.3	44
27	Extracellular Vesicles: New Players in Lung Immunity. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 560-565.	2.9	44
28	Involvement of Lamin B1 Reduction in Accelerated Cellular Senescence during Chronic Obstructive Pulmonary Disease Pathogenesis. Journal of Immunology, 2019, 202, 1428-1440.	0.8	42
29	Involvement of GPx4-Regulated Lipid Peroxidation in Idiopathic Pulmonary Fibrosis Pathogenesis. Journal of Immunology, 2019, 203, 2076-2087.	0.8	40
30	Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis. Cell Reports, 2018, 24, 3296-3311.e6.	6.4	39
31	Ubiquitin Ligases in Cancer Immunotherapy – Balancing Antitumor and Autoimmunity. Trends in Molecular Medicine, 2019, 25, 428-443.	6.7	35
32	Early prediction of COVIDâ€19 severity using extracellular vesicle COPB2. Journal of Extracellular Vesicles, 2021, 10, e12092.	12.2	27
33	Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer. Oncotarget, 2015, 6, 3335-3345.	1.8	26
34	Pulmonary Actinomyces graevenitzii infection presenting as organizing pneumonia diagnosed by PCR analysis. Journal of Medical Microbiology, 2012, 61, 1156-1158.	1.8	25
35	Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study. Journal of Asthma and Allergy, 2021, Volume 14, 609-618.	3.4	23
36	Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2015, 14, 1414-1423.	4.1	22

Үи Ғијіта

#	Article	IF	CITATIONS
37	Chaperoneâ€mediated autophagy receptor modulates tumor growth and chemoresistance in non–small cell lung cancer. Cancer Science, 2020, 111, 4154-4165.	3.9	22
38	The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors. Nature Communications, 2021, 12, 5397.	12.8	20
39	Intercellular Communication by Vascular Endothelial Cell-Derived Extracellular Vesicles and Their MicroRNAs in Respiratory Diseases. Frontiers in Molecular Biosciences, 2020, 7, 619697.	3.5	19
40	Chaperone-Mediated Autophagy Suppresses Apoptosis via Regulation of the Unfolded Protein Response during Chronic Obstructive Pulmonary Disease Pathogenesis. Journal of Immunology, 2020, 205, 1256-1267.	0.8	18
41	Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report. Cancer Immunology, Immunotherapy, 2020, 69, 2033-2039.	4.2	13
42	Involvement of Parkinâ€mediated mitophagy in the pathogenesis of chronic obstructive pulmonary diseaseâ€related sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1864-1882.	7.3	13
43	Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma. Cancers, 2019, 11, 768.	3.7	12
44	Role of chaperone-mediated autophagy in the pathophysiology including pulmonary disorders. Inflammation and Regeneration, 2021, 41, 29.	3.7	12
45	Extracellular vesicles in smoking-related lung diseases. Oncotarget, 2015, 6, 43144-43145.	1.8	11
46	Extracellular vesicle-mediated cellular crosstalk in lung repair, remodelling and regeneration. European Respiratory Review, 2022, 31, 210106.	7.1	11
47	Impaired TRIM16-Mediated Lysophagy in Chronic Obstructive Pulmonary Disease Pathogenesis. Journal of Immunology, 2021, 207, 65-76.	0.8	8
48	Fucosyltransferase Induction during Influenza Virus Infection Is Required for the Generation of Functional Memory CD4+ T Cells. Journal of Immunology, 2018, 200, 2690-2702.	0.8	7
49	Response of paraneoplastic nephrotic syndrome to corticosteroids combined with chemotherapy for advanced lung cancer: a case report and literature review. International Cancer Conference Journal, 2012, 1, 88-92.	0.5	0
50	Extracellular vesicles in fibrotic diseases: New applications for fibrosis diagnosis and treatment. , 2020, , 307-323.		0
51	The Potential Role of MicroRNA-Based Therapy for Lung Cancer Stem Cells. , 2014, , 83-98.		0
52	Challenges and Strategies for Pulmonary Delivery of MicroRNA-Based Therapeutics. , 2014, , 413-428.		0
53	RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors. Blood, 2020, 136, 31-32.	1.4	0